Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC
Frontiers in Oncology · 25.05.2026 · 16
DOI: 10.3389/fonc.2026.1766544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 25.05.2026. Verfasst von Lorenzo De Sanctis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medicine and Surgery Department, University of Milan Bicocca, Milano, Italy. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
To assess the efficacy of progression-directed radiation therapy (PDRT) in patients with oligoprogressive non-small cell lung cancer (NSCLC), with particular focus on disease progression and changes in systemic therapy. Materials and methods From January 2020 to October 2025, a retrospective single-center analysis was conducted at our Institution, including NSCLC patients treated with PDRT for oligoprogressive disease. Oligoprogression was defined as progression involving fewer than five extracranial lesions or a total intracranial disease volume of ≤14 cc, following an initial response to systemic treatment. The primary endpoint was event-free survival (EFS), defined as the occurrence of any of the following: change in systemic therapy, progression within 6 months, or development of >3 progressive lesions. Multivariate Cox regression models were applied to identify predictors of oncological outcomes.
Results
Eighty-seven patients were included, with a median age of 68 years (range: 43–87) and a median follow-up of 14 months. Adenocarcinoma was the predominant histology (75 cases, 86.2%), followed by squamous cell carcinoma (12 cases, 13.8%). PDRT was administered after first-line systemic therapy in 61 patients (70.1%). At the last assessment, 12 (13.8%) patients achieved a complete response, 29 (33.3%) a partial response, and 46 (52.9%) stable disease. The median time to event, death or last follow-up was 5 months (range: 1–48), with a one-year actuarial EFS rate of 52.1% (95% CI: 46.4–57.8%). Median time to next treatment (TTNT) was 8 months (range: 1–68), while median progression-free survival was 5 months (range: 1–39). On multivariate analysis, both PDRT directed at the primary tumor (HR = 0.28, 95% CI: 0.12–0.66; p < 0.01) and achieving a complete response prior to oligoprogression (HR = 0.31, 95% CI: 0.10–0.95; p = 0.04) were significantly associated with improved EFS. Conversely, chemotherapy use (HR = 2.33, 95% CI: 1.21–4.48; p = 0.02) and larger CTV volumes (HR = 1.01, 95% CI: 1.0004–1.0111; p = 0.03) were associated with worse outcomes.
Conclusions
PDRT achieved a median EFS of 5 months and extended the median time to next systemic therapy to 8 months. These findings suggest that PDRT may represent an effective approach to maintaining disease control and postponing systemic treatment in oligoprogressive NSCLC. Larger, prospective studies with extended follow-up are warranted to confirm these results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medicine and Surgery Department, University of Milan Bicocca, Milano, Italy.
- Radiation Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Gerardo Dei Tintori, Monza, Italy.
- Medical Physics, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Gerardo Dei Tintori, Monza, Italy.
- Medical Oncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Gerardo dei Tintori, Monza, Italy.
Zitieren
APA
De Sanctis, L., Colciago, R. R., Rossano, G., Ferrari, M., Mombelli, M., Manno, I., Ferrario, F., Saufi, S., Faccenda, V., Panizza, D., Passarella, G., Canova, S., Cortinovis, D. L., & Arcangeli, S. (2026). Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1766544
Vancouver
De Sanctis L, Colciago RR, Rossano G, Ferrari M, Mombelli M, Manno I, et al. Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1766544
BibTeX
@article{DeSanctis2026,
author = {De Sanctis, Lorenzo and Colciago, Riccardo Ray and Rossano, Giulia and Ferrari, Matteo and Mombelli, Matteo and Manno, Ilenia and Ferrario, Federica and Saufi, Sara and Faccenda, Valeria and Panizza, Denis and Passarella, Gaia and Canova, Stefania and Cortinovis, Diego Luigi and Arcangeli, Stefano},
title = {Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1766544}
}
EUVIMED